Cargando…

Assessment of a polygenic hazard score for the onset of pre-clinical Alzheimer’s disease

ABSTRACT: BACKGROUND: With a growing number of loci associated with late-onset (sporadic) Alzheimer’s disease (AD), the polygenic contribution to AD is now well established. The development of polygenic risk score approaches have shown promising results for identifying individuals at higher risk of...

Descripción completa

Detalles Bibliográficos
Autores principales: Vacher, Michael, Doré, Vincent, Porter, Tenielle, Milicic, Lidija, Villemagne, Victor L., Bourgeat, Pierrick, Burnham, Sam C., Cox, Timothy, Masters, Colin L., Rowe, Christopher C., Fripp, Jurgen, Doecke, James D., Laws, Simon M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9134703/
https://www.ncbi.nlm.nih.gov/pubmed/35619096
http://dx.doi.org/10.1186/s12864-022-08617-2
_version_ 1784713816144084992
author Vacher, Michael
Doré, Vincent
Porter, Tenielle
Milicic, Lidija
Villemagne, Victor L.
Bourgeat, Pierrick
Burnham, Sam C.
Cox, Timothy
Masters, Colin L.
Rowe, Christopher C.
Fripp, Jurgen
Doecke, James D.
Laws, Simon M.
author_facet Vacher, Michael
Doré, Vincent
Porter, Tenielle
Milicic, Lidija
Villemagne, Victor L.
Bourgeat, Pierrick
Burnham, Sam C.
Cox, Timothy
Masters, Colin L.
Rowe, Christopher C.
Fripp, Jurgen
Doecke, James D.
Laws, Simon M.
author_sort Vacher, Michael
collection PubMed
description ABSTRACT: BACKGROUND: With a growing number of loci associated with late-onset (sporadic) Alzheimer’s disease (AD), the polygenic contribution to AD is now well established. The development of polygenic risk score approaches have shown promising results for identifying individuals at higher risk of developing AD, thereby facilitating the development of preventative and therapeutic strategies. A polygenic hazard score (PHS) has been proposed to quantify age-specific genetic risk for AD. In this study, we assessed the predictive power and transferability of this PHS in an independent cohort, to support its clinical utility. RESULTS: Using genotype and imaging data from 780 individuals enrolled in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study, we investigated associations between the PHS and several AD-related traits, including 1) cross-sectional Aβ-amyloid (Aβ) deposition, 2) longitudinal brain atrophy, 3) longitudinal cognitive decline, 4) age of onset. Except in the cognitive domain, we obtained results that were consistent with previously published findings. The PHS was associated with increased Aβ burden, faster regional brain atrophy and an earlier age of onset. CONCLUSION: Overall, the results support the predictive power of a PHS, however, with only marginal improvement compared to apolipoprotein E alone. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12864-022-08617-2.
format Online
Article
Text
id pubmed-9134703
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-91347032022-05-27 Assessment of a polygenic hazard score for the onset of pre-clinical Alzheimer’s disease Vacher, Michael Doré, Vincent Porter, Tenielle Milicic, Lidija Villemagne, Victor L. Bourgeat, Pierrick Burnham, Sam C. Cox, Timothy Masters, Colin L. Rowe, Christopher C. Fripp, Jurgen Doecke, James D. Laws, Simon M. BMC Genomics Research ABSTRACT: BACKGROUND: With a growing number of loci associated with late-onset (sporadic) Alzheimer’s disease (AD), the polygenic contribution to AD is now well established. The development of polygenic risk score approaches have shown promising results for identifying individuals at higher risk of developing AD, thereby facilitating the development of preventative and therapeutic strategies. A polygenic hazard score (PHS) has been proposed to quantify age-specific genetic risk for AD. In this study, we assessed the predictive power and transferability of this PHS in an independent cohort, to support its clinical utility. RESULTS: Using genotype and imaging data from 780 individuals enrolled in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study, we investigated associations between the PHS and several AD-related traits, including 1) cross-sectional Aβ-amyloid (Aβ) deposition, 2) longitudinal brain atrophy, 3) longitudinal cognitive decline, 4) age of onset. Except in the cognitive domain, we obtained results that were consistent with previously published findings. The PHS was associated with increased Aβ burden, faster regional brain atrophy and an earlier age of onset. CONCLUSION: Overall, the results support the predictive power of a PHS, however, with only marginal improvement compared to apolipoprotein E alone. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12864-022-08617-2. BioMed Central 2022-05-26 /pmc/articles/PMC9134703/ /pubmed/35619096 http://dx.doi.org/10.1186/s12864-022-08617-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Vacher, Michael
Doré, Vincent
Porter, Tenielle
Milicic, Lidija
Villemagne, Victor L.
Bourgeat, Pierrick
Burnham, Sam C.
Cox, Timothy
Masters, Colin L.
Rowe, Christopher C.
Fripp, Jurgen
Doecke, James D.
Laws, Simon M.
Assessment of a polygenic hazard score for the onset of pre-clinical Alzheimer’s disease
title Assessment of a polygenic hazard score for the onset of pre-clinical Alzheimer’s disease
title_full Assessment of a polygenic hazard score for the onset of pre-clinical Alzheimer’s disease
title_fullStr Assessment of a polygenic hazard score for the onset of pre-clinical Alzheimer’s disease
title_full_unstemmed Assessment of a polygenic hazard score for the onset of pre-clinical Alzheimer’s disease
title_short Assessment of a polygenic hazard score for the onset of pre-clinical Alzheimer’s disease
title_sort assessment of a polygenic hazard score for the onset of pre-clinical alzheimer’s disease
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9134703/
https://www.ncbi.nlm.nih.gov/pubmed/35619096
http://dx.doi.org/10.1186/s12864-022-08617-2
work_keys_str_mv AT vachermichael assessmentofapolygenichazardscorefortheonsetofpreclinicalalzheimersdisease
AT dorevincent assessmentofapolygenichazardscorefortheonsetofpreclinicalalzheimersdisease
AT portertenielle assessmentofapolygenichazardscorefortheonsetofpreclinicalalzheimersdisease
AT miliciclidija assessmentofapolygenichazardscorefortheonsetofpreclinicalalzheimersdisease
AT villemagnevictorl assessmentofapolygenichazardscorefortheonsetofpreclinicalalzheimersdisease
AT bourgeatpierrick assessmentofapolygenichazardscorefortheonsetofpreclinicalalzheimersdisease
AT burnhamsamc assessmentofapolygenichazardscorefortheonsetofpreclinicalalzheimersdisease
AT coxtimothy assessmentofapolygenichazardscorefortheonsetofpreclinicalalzheimersdisease
AT masterscolinl assessmentofapolygenichazardscorefortheonsetofpreclinicalalzheimersdisease
AT rowechristopherc assessmentofapolygenichazardscorefortheonsetofpreclinicalalzheimersdisease
AT frippjurgen assessmentofapolygenichazardscorefortheonsetofpreclinicalalzheimersdisease
AT doeckejamesd assessmentofapolygenichazardscorefortheonsetofpreclinicalalzheimersdisease
AT lawssimonm assessmentofapolygenichazardscorefortheonsetofpreclinicalalzheimersdisease